Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK HIV vaccine 732462 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | OTHER | Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study |
| Group B | OTHER | Subjects who were administered placebo in primary studies and who accepted to participate in this study |
| Name | Type | Description |
|---|---|---|
| Blood collection | PROCEDURE | Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick. |
| GSK HIV vaccine 732462 | BIOLOGICAL | No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies. |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * HIV-infected subject. * Previous participation in a study evaluating GSK HIV vaccine 732462. * Written informed consent obtained from the subject. Exclusion Criteria: The following criteria should be check...
GSK HIV vaccine 732462 is an investigational vaccine being studied for the prevention of AIDS, a condition caused by HIV infection. It is currently in Phase 1 clinical development and is not yet approved for use.
GSK HIV vaccine 732462 is developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
GSK HIV vaccine 732462 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the vaccine remains under evaluation.
GSK HIV vaccine 732462 has been studied in one clinical trial, NCT01092611, titled "Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine." This Phase 1 trial, which enrolled 190 participants, has been completed and included sites in the United States, France, Germany, and Spain.
GSK HIV vaccine 732462 is classified as a monoclonal antibody modality, though it is being developed as a vaccine for AIDS. The trial NCT01092611 evaluated long-term follow-up of participants from studies assessing this vaccine candidate.